和鉑醫藥-B(02142.HK)與VISTERRA, INC.訂立授權協議
格隆匯6月12日丨和鉑醫藥-B(02142.HK)公告,公司全資子公司諾納生物(美國)公司已與Visterra, Inc.訂立授權協議,以利用諾納生物的專有僅重鏈抗體(HCAb)Harbour Mice®技術平臺,推進Visterra的下一代免疫介導性及自身免疫疾病的生物治療藥物管線。
諾納生物的HCAb Harbour Mice®平臺可生成全人源僅重鏈抗體,具有降低免疫原性及提高下一代生物治療藥物的多效性等主要優勢。該創新平臺已獲臨牀驗證,並得到全球合作夥伴的廣泛認可。
Visterra是一家生物製品研究及早期臨牀開發生物技術公司,致力於開發創新抗體療法,用於治療免疫介導性腎臟疾病及其他難治疾病患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.